Results 231 to 240 of about 39,389 (304)

The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose. [PDF]

FEBS Lett
Bashtanova U, Duer MJ.
europepmc   +1 more source

TCDD-Inducible Poly [ADP-Ribose] Polymerase [PDF]

, 2020
openaire   +1 more source

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Clinical Cancer Research, 2010
C. Redon, A. Nakamura, Yong-Wei Zhang, J. Ji, W. Bonner, R. Kinders, R. Parchment, J. Doroshow, Y. Pommier   +8 more
semanticscholar   +1 more source

Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone. [PDF]

Acta Crystallogr F Struct Biol Commun, 2014
Aoyagi-Scharber M, Gardberg AS, Yip BK, Wang B, Shen Y, Fitzpatrick PA.   +5 more
europepmc   +1 more source

Poly [ADP-Ribose] Polymerase 1 p85 [PDF]

, 2020
openaire   +1 more source

Chromatin relaxation dynamics and histone PTMs in the early DNA damage response. [PDF]

Cancer Biol Med
Qian J, Xie Z, Zhou L, Zhu WG.
europepmc   +1 more source

The nicotinamide hypothesis revisited-plant defense signaling integrating PARP, nicotinamide, nicotinic acid, epigenetics, and glutathione. [PDF]

FEBS Lett
Berglund T, Ohlsson AB.
europepmc   +1 more source

Identifying Direct Protein Targets of Poly-ADP-Ribose Polymerases (PARPs) Using Engineered PARP Variants-Orthogonal Nicotinamide Adenine Dinucleotide (NAD+) Analog Pairs. [PDF]

Curr Protoc Chem Biol, 2015
Carter-O'Connell I, Cohen MS.
europepmc   +1 more source

Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation

, 2001
Francisco García Soriano, László Virág, Csaba Szabó   +2 more
openalex   +2 more sources

Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis. [PDF]

Discov Oncol
Wang X, Ding G, He J, Huang Y, Wang Q.
europepmc   +1 more source